Vivo Capital’s Akero Therapeutics AKRO Stock Holding History

Vivo Capital’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-434,689	Closed	-$20.6M	–	48
2025 Q3	$20.6M	Hold	434,689	–	–	1.66%	20
2025 Q2	$23.2M	Buy	434,689 +233,521	+116%	+$10.6M	2.37%	10
2025 Q1	$8.14M	Buy	+201,168	New	+$8.53M	1.08%	22
2021 Q2	–	Sell	-673,280	Closed	-$19.5M	–	60
2021 Q1	$19.5M	Buy	673,280 +39,854	+6%	+$1.21M	0.69%	30
2020 Q4	$16.3M	Buy	633,426 +61,593	+11%	+$1.71M	0.73%	32
2020 Q3	$17.6M	Sell	571,833 -19,336	-3%	-$676K	1.02%	28
2020 Q2	$14.7M	Sell	591,169 -217,078	-27%	-$4.96M	1.06%	26
2020 Q1	$17.1M	Buy	+808,247	New	+$17.3M	1.55%	16

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vivo Capital's AKRO Position: Q4 2025 in Review

Vivo Capital sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 434,689 shares — an estimated $20.6M sold.

Vivo Capital first reported a position in AKRO in Q1 2020 and held it in 8 quarters. The position peaked at $23.2M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Vivo Capital reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Vivo Capital sold 434,689 Akero Therapeutics shares in Q4 2025, an estimated $20.6M.
Vivo Capital first reported a position in Akero Therapeutics in Q1 2020 and held it in 8 quarters.
Vivo Capital's Akero Therapeutics position peaked at $23.2M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Vivo Capital's 13F filing for Q4 2025, filed 13 Feb 2026.